Typewriter Therapeutics Raises USD 56 Million Series A to Advance TPRT RNA Gene Insertion Platform for In Vivo CAR-T and Liver Diseases

Typewriter Therapeutics announced the completion of a USD 56 million Series A financing to develop its RNA-based gene insertion technology platform, with R&D focused on in vivo CAR-T therapies and hereditary liver diseases. Built on the company’s proprietary Targeted Primed Reverse Transcription (TPRT) platform, the all-RNA approach enables in vivo gene editing without viral vectors — and the company plans to initiate its first non-human primate studies by the end of 2026.

Financing Overview

Technology Platform: Targeted Primed Reverse Transcription (TPRT)

• Foundation: The TPRT platform is based on the R2 retrotransposon, re-engineered for therapeutic gene insertion
• All-RNA Design: The therapeutic approach uses no DNA and no viral vectors — consisting of:
  • A payload mRNA encoding the R2 protein
  • A separate RNA carrying the therapeutic gene, flanked by sequences that recruit the R2 protein
• Mechanism: Upon cellular entry, the two components assemble into an active complex that inserts the therapeutic gene at a specific genomic site; the R2 protein machinery then degrades along with the mRNA, leaving only the inserted gene at the target location
• Key Attributes: Designed to deliver safe, durable, and redosable gene medicines — addressing persistent limitations of conventional viral-vector gene therapy
• Strategic Applications: The redosability and vector-free profile hold particular potential for in vivo CAR-T therapies, where manufacturing and vector constraints currently limit scalability

Development Status & Pipeline Outlook

• R&D efforts are concentrated on two front-line areas: in vivo CAR-T therapies and hereditary liver diseases
• The company’s mission spans gene medicines with curative potential for cancer, autoimmune diseases, and severe genetic disorders
• Non-human primate studies are slated to begin by the end of 2026, a key preclinical milestone that would provide the first proof points for the TPRT platform in a clinically relevant species

Market Impact & Outlook

• Vector-free differentiation: By eliminating viral vectors, the TPRT platform addresses immunogenicity, manufacturing complexity and redosing barriers that constrain much of today’s gene therapy landscape
• In vivo CAR-T opportunity: Generating CAR-T cells directly inside the body could transform a therapy class currently defined by complex, costly ex vivo manufacturing
• Capital validation: A USD 56 million Series A reflects investor confidence in the retrotransposon-based approach at an early but strategically significant stage
• Competitive landscape: Typewriter Therapeutics competes in a rapidly evolving field of next-generation gene writing technologies, where durability and redosability are emerging as decisive differentiators against AAV-based incumbents

Forward‑Looking Statements: This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding technology development, preclinical timelines and therapeutic potential are forward-looking and subject to risks and uncertainties, including preclinical and clinical outcomes, regulatory pathways and competitive developments. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.-Fineline Info & Tech